Skip to main content
. 2023 Oct 17;5(11):405–414. doi: 10.1253/circrep.CR-23-0071

Figure 2.

Figure 2.

Primary outcome. (A) Percentage changes in the maximum orthogonal abdominal aortic aneurysm (AAA) diameter (measured by plain multislice computed tomography) at the 24-month follow-up. The difference between the candesartan (CAN; red circles) and amlodipine (AML; blue triangles) groups (at the time point of 24 months) was 1.87% (95% confidence interval [CI] −1.22%, 4.95%; P=0.233). At 24 months, the percentage change in AAA diameter was +8.4% (95% CI 6.23%, 10.59%) in the CAN group and +6.5% (95% CI 3.65%, 9.43%) in the AML group. (B) Subanalysis of the effect of β-blockers on the percentage change in AAA diameter (Table 1). There was no significant difference between the CAN and AML groups in patients who were not taking β-blockers (Table 1), despite a trend indicating that AML suppressed AAA growth more strongly than CAN (P=0.18). Data are the mean±SD.